Clin2
NCT06707194Possibly a fitRecruiting

Penicillin plus etanercept for spondyloarthritis

Spondyloarthritis (SpA)Ankylosing Spondylitis (AS)

Treatments studied

Part of Bones, joints & muscles clinical trials.

This trial tests whether adding a common antibiotic (benzathine penicillin) to a standard biologic drug (etanercept) can better treat spondyloarthritis. It may help if you have active disease and are free of certain infections.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
340 people
Ages
18 years to 59 years
Study type
Interventional

Who can take part

  • You are between 18 and 59 years old.
  • You have a diagnosis of spondyloarthritis (a type of arthritis that mainly affects the spine).
  • Your disease is active, meaning you have symptoms like pain and stiffness.
  • You do not have any active infections, such as a cold, strep throat, or tuberculosis.
  • You are not pregnant, planning to become pregnant, or breastfeeding.
  • You do not have severe liver or kidney problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07556224Recruiting
Combining Chinese and Western Medicine for Ankylosing Spondylitis

This study tests whether combining traditional Chinese medicine with standard Western treatments can help ankylosing spondylitis (a condition causing spine stiffness and inflammation) work better and improve your quality of life. Researchers will follow patients over time to see how well this combined approach works.

Beijing, Beijing Municipality
NCT07509775Recruiting
Chinese medicine and Western medicine for Ankylosing Spondylitis

This study tests if combining traditional Chinese medicine with standard Western medicine can better treat ankylosing spondylitis. The goal is to see if this approach can reduce inflammation and improve your symptoms, such as back pain and stiffness.

Beijing, Beijing, China
NCT05303285Recruiting· Phase 4
Secukinumab for active ankylosing spondylitis in Chinese adults

This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.

Wuhan, Hubei
NCT05592574Recruiting
Test of a biologic for active spondyloarthritis

This trial studies whether adding a biologic medicine (targeted therapy) can help people with active spondyloarthritis when standard anti-inflammatory pain medicines (NSAIDs) have not worked well enough. It focuses on people with ongoing symptoms despite trying at least two NSAIDs.

Nice
NCT06833112Not yet recruiting· Phase 4
Two immune blockers for ankylosing spondylitis

This study tests whether combining two types of immune-blocking drugs (an IL-17 inhibitor and a TNF inhibitor) works better than either alone for treating ankylosing spondylitis. It is for people whose symptoms are not well controlled with NSAIDs.

Guiyang, Guizhou
NCT07396194Not yet recruiting
Study for people with ankylosing spondylitis

This trial is for people with ankylosing spondylitis (a type of arthritis that affects the spine) who are otherwise healthy. It may test a treatment to see if it helps control symptoms, whether your disease is active or stable.

Hear when a new Spondyloarthritis (SpA) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.